THU0190 METHOTREXATE THERAPY IS NOT ASSOCIATED WITH AN INCREASED RISK OF LIVER FIBROSIS ASSESSED BY THE FIBROSIS-4 INDEX
Authors: J. Avouac, R. Degrave, H. Vergneault, Y. Allanore
Journal: Annals of the Rheumatic Diseases (2020)

Background: Methotrexate (MTX) holds a unique place in the management of rheumatoid arthritis (RA) given its favorable balance between efficacy and safety. However, conflicting data still suggest a potential risk of MTX-induced long-term liver fibrosis. The fibrosis-4 (FIB-4) index was originally proposed as a simple and non-invasive marker of liver fibrosis in HIV/HCV co-infection. In patients with RA, FIB-4 values have been correlated to the amount of histologic liver lesions, suggesting that this index may be a valuable marker to diagnose liver disease in RA patients (1). Objectives: To estimate the amount of scarring in the liver with the FIB-4 index in RA patients on maintenance therapy with MTX. Methods: We performed a cross-sectional study including successive RA patients hospitalized in the Rheumatology department of Cochin Hospital for a 12-month period. Data on liver function, disease activity, hepatotoxic and cardiovascular risk factors were systematically collected. The FIB-4 index was calculated according the following formula: (age(years) × AST(U/L)/platelet (PLT) (109/L) × √ALT(U/L)). Using a lower cutoff value of 1.45, a FIB-4 score &lt;1.45 had a negative predictive value of 90% for advanced fibrosis in the patient cohort in which this formula was first validated. In contrast, a FIB-4 &gt;3.25 had a 97% specificity and a positive predictive value of 65% for advanced fibrosis (2). Results: We included 170 patients with established RA: 141 (83%) were women, the mean age was 59+/-12 years and the mean disease duration was 15+/-11 years. Positive rheumatoid factors and anti-CCP antibodies were detected in 134 patients (79%). 102 patients (60%) were treated with methotrexate, with a mean dose of 10.0+/-8.4 mg/week, a mean treatment duration of 9.5+/-10.3 years and a cumulative dose of 5.3+/-5.1g. 23 patients (13.5%) received conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than MTX, 112 (66%) corticosteroids (99 with a dose &lt; 10 mg/day) and 85 targeted biologic DMARDs (bDMARDs) (50%). The mean FIB-4 value was 1.24+/-0.57, with 120 patients (71%) with value &lt;1.45, 49 (29%) with values ranging from 1.45 to 3.25 and a single patient with FIB-4 &gt;3.25. The FIB-4 was low and not significantly different between patients receiving MTX, patients previously treated with MTX and patients never treated with MTX (median 1.1, 1.25 and 1.18, respectively, p=0.709). This result was not modified after adjustment on treatments with other csDMARDs, corticosteroids, and bDMARDs. No correlation was observed between FIB-4 values and the cumulative dose of MTX (r=0.09, p=0.271). The FIB-4 index was low and similar between patients receiving cumulative MTX doses &lt;5g, between 5 and 10g and 10g (Figure 1). The cumulative dose of MTX was not significantly higher in patients with a FIB-4 index &gt;1.45 (median cumulative MTX dose 5.5g vs. 3.5g, p=0.302). No association was detected between the FIB-4 index and parameters of disease activity (DAS28, ESR and CRP levels), the body mass index, traditional cardiovascular risk factors and metabolic syndrome. Figure 1. Fibrosis-4 index according to the cumulative dose of methotrexate in patients with rheumatoid arthritis Conclusion: RA patients with long-term maintenance MTX therapy have low FIB-4 values suggesting that MTX is not associated with an increased risk of advanced liver fibrosis. References: [1]Miyata et al, Mod Rheumatol 2019 [2]Sterling et al, Hepatology 2006 Disclosure of Interests: Jérôme Avouac Grant/research support from: Pfizer, Bristol Myers Squibb, Consultant of: Sanofi, Bristol Myers Squibb, Abbvie, Boerhinger, Nordic Pharma, Speakers bureau: Sanofi, Bristol Myers Squibb Abbvie, MSD, Pfizer, Nordic Pharma, Raphael Degrave: None declared, Hélène Vergneault: None declared, Yannick Allanore Shareholder of: Sanofi, Roche, Consultant of: Actelion, Bayer, BMS, Boehringer Ingelheim, Inventiva, Sanofi